Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CF PharmTechHKSE:02652 +0.81%15 Buyback Yield % is -9.16 as of Aug. 11, 2026. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 275 Drug Manufacturers companies, CF PharmTech ranks worse than 74.55% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for CF PharmTech's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech Buyback Yield % Chart
CF PharmTech Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Buyback Yield %
0.00
0.00
0.00
-4.12
CF PharmTech Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
Buyback Yield %
0.00
0.00
0.00
-4.12
HKSE:02652 vs ZTS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CF PharmTech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CF PharmTech Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CF PharmTech's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where CF PharmTech's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech (HKSE:02652) has a Buyback Yield % of -9.16 as of Aug. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CF PharmTech and its competitors. According to the industry distribution chart, CF PharmTech ranks #205 out of 275 companies in the Drug Manufacturers industry, placing it in the top 74.5%.
Is CF PharmTech's Buyback Yield % too high?
CF PharmTech's current Buyback Yield % is -9.16. Based on the distribution chart, CF PharmTech ranks #205 out of 275 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CF PharmTech ranks #205 out of 275 companies for Buyback Yield %. This places CF PharmTech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CF PharmTech and its competitors. CF PharmTech's current Buyback Yield % is -9.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current Buyback Yield % of -9.16. The current Buyback Yield % is -9.16. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current Buyback Yield % is -9.16 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score
Get the complete analysis for HKSE:02652
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02652 has been successfully added to your 
